NSAIDs and Prostaglandins

SECTION 1: Learning Outcomes

• Recognise the signs of inflammation.

• Identify the enzymes in the arachidonic acid pathway inhibited by steroids and by NSAIDs.

• Explain why COX-1 inhibition by non-selective NSAIDs leads to GI ulcers and slows blood clotting.

• Name 3 COX-2 selective drugs and describe their advantages as well as the problems that emerged.

SECTION 2: Inflammation – The Body's Response

• Definition: The body's response to harmful stimuli or cell damage.

• Key Signs and Effects:

  • Increased blood flow: Causes redness (rubor) and heat (calor).

  • Extra fluid exudation: Brings immune cells, causing swelling (tumor).

  • Release of mediators: Leads to pain (dolor) and potential loss of function (functio laesa).

• Examples: Bee sting, stubbed toe, burnt finger.

• Visual (Page 5): The page shows the classic "five signs of inflammation" likely illustrated with icons or text: Redness, Heat, Swelling, Pain, Loss of Function.

SECTION 3: Inflammatory Disorders

• Inflammation underlies many diseases, often indicated by the suffix ".itis".

• Examples:

  • Rheumatoid arthritis: Inflamed joints.

  • Asthma: Inflamed bronchial tubes.

  • Crohn's disease: Inflamed lining of the digestive system.

  • Ankylosing spondylitis: Inflamed spinal joints.

SECTION 4: The Arachidonic Acid Pathway

• Step 1 – Arachidonic Acid Release: When cells are injured, membrane phospholipids are hydrolysed by the enzyme Phospholipase A2 (PLA₂) to release arachidonic acid.

  • Visual (Page 6): A diagram shows a cell membrane with phospholipids. PLA₂ acts on them, releasing arachidonic acid (likely depicted as a wavy line or molecule).

• Step 2 – Prostaglandin Synthesis: Cyclooxygenase (COX) converts arachidonic acid into Prostaglandin H2 (PGH₂), a key precursor.

  • Visual (Page 7): A flowchart shows arachidonic acid entering a "COX" enzyme box and emerging as PGH₂.

SECTION 5: How Anti-Inflammatory Drugs Target the Pathway

5.1 Glucocorticoids (Steroids)

• Mechanism: Indirect inhibition. Steroids (e.g., dexamethasone) bind to the glucocorticoid receptor and activate genes that promote synthesis of lipocortin I, an inhibitor of PLA₂.

• Visual (Page 8): A diagram illustrates a steroid molecule entering the nucleus, activating gene transcription for lipocortin I, which then blocks PLA₂.

• Fun Fact: Snake venom (e.g., from Russell's viper, horned viper) often contains PLA₂ enzymes, which contribute to tissue damage and toxicity.

  • Visual (Page 9): An image of a snake, likely highlighting the connection between its venom and the inflammatory pathway.

5.2 NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)

• Primary Target: Cyclooxygenase (COX) enzymes.

• The Two Isoforms:

  • COX-1: Constitutively expressed ("housekeeping" enzyme). It produces prostaglandins needed for normal physiological functions (gastric protection, platelet aggregation).

  • COX-2: Inducible; its synthesis increases in injured cells as part of the inflammatory response.

  • Visual (Pages 11-12): Two similar enzyme structures are shown side-by-side, labeled COX-1 and COX-2. The text emphasizes that both make PGH₂, but COX-2 levels rise with injury.

SECTION 6: Consequences of COX-1 Inhibition by Traditional NSAIDs

6.1 Gastric Ulcers

• Mechanism: COX-1 produces PGH₂, which is converted to Prostacyclin (PGI₂). PGI₂ protects the gastric mucosa from acid by maintaining blood flow and mucus secretion.

• Problem: Traditional NSAIDs inhibit COX-1, reducing PGI₂, leaving the stomach lining vulnerable to acid, leading to ulcers and GI bleeding.

• Visual (Page 13-14): A diagram shows PGH₂ from COX-1 being converted to PGI₂, which forms a protective layer over stomach cells. An NSAID molecule is shown blocking COX-1, breaking this protection.

• High-Risk Traditional NSAIDs: Indomethacin, ketoprofen, flurbiprofen.

• List of Traditional NSAIDs (with year of introduction):

  • Aspirin (1899)

  • Ibuprofen (1969)

  • Indomethacin (1965)

  • Naproxen (1976)

  • Ketoprofen (1986)

  • Flurbiprofen (1987)

  • Visual (Pages 15-16): These drugs are listed, likely with icons or chemical structures. A key point is made: COX-2 inhibition prevents inflammation; COX-1 inhibition leads to ulcers.

6.2 Impaired Blood Clotting

• Mechanism: COX-1 also produces PGH₂ for conversion to Thromboxane A2 (TXA₂) in platelets, which promotes platelet aggregation and clotting.

• Aspirin's Special Action: Aspirin irreversibly acetylates the active site of COX-1 (and COX-2, less effectively). This permanently inactivates the enzyme in platelets (which cannot synthesize new protein), slowing blood clotting for the platelet's 7-10 day lifespan.

• Visual (Pages 17-21):

  • Page 17: Shows PGH₂ from COX-1 converted to TXA₂, promoting a clotting cascade.

  • Pages 18-21: Show the molecular structure of the COX enzyme dimer (two subunits). Diagrams illustrate:

    • The active site and an allosteric site on different monomers.

    • Aspirin (acetylsalicylic acid) covalently binding to a serine residue in the active site, causing irreversible inhibition.

    • Other NSAIDs (e.g., diclofenac, indomethacin) binding reversibly to the active site, while some (naproxen, flurbiprofen) bind to an allosteric site.

SECTION 7: The Development & Downfall of COX-2 Selective Inhibitors (Coxibs)

7.1 The Goal and Initial Promise

• Rationale: Develop drugs that selectively inhibit COX-2 (the inducible, inflammatory isoform) while sparing COX-1 (the protective, housekeeping isoform).

• Goal: Relieve inflammation and pain without causing gastric ulcers.

• First-Generation Coxibs:

  • Celecoxib (Celebrex, Pfizer, 1998) – COX-2 selective.

  • Rofecoxib (Vioxx, Merck, 1999) – Highly COX-2 selective.

  • Visual (Page 24): Chemical structures or logos for Celecoxib and Rofecoxib are shown.

7.2 Molecular Basis of Selectivity

• Structural Difference: COX-2 has a more spacious hydrophilic side-pocket in its active site compared to COX-1.

• Coxib Design: They contain a protruding aromatic substituent (e.g., a sulfonamide or sulfone group). This "bulky bit" fits perfectly into COX-2's larger side-pocket but cannot fit into COX-1's smaller pocket, which is blocked by a larger isoleucine residue (replacing a valine found in COX-2).

• Analogy (Page 25): Aspirin is likened to "Cinderella's slipper" – a good fit for COX-1. Celecoxib is an "ugly sister" – a poor fit for COX-1 but a perfect fit for COX-2.

• Visual (Pages 26-27): Diagrams contrast the active sites of COX-1 and COX-2. COX-2's larger pocket accommodates the coxib's bulky group, while COX-1's smaller pocket, with an isoleucine "bump," blocks it.

7.3 Cardiovascular (CV) Risks and Controversy

• The Scandal: Merck was found to have hidden data showing a 5-fold increase in myocardial infarction (heart attack) with rofecoxib (Vioxx) compared to naproxen.

• Outcome: Vioxx was withdrawn in 2004 after 5 years on the market, linked to ~100,000 cases of severe heart disease.

• Broader Discovery: Subsequent research revealed that traditional NSAIDs could also have high CV risks. The risk is not exclusive to coxibs.

• Visual (Pages 28-31):

  • Page 28: Shows logos for Celecoxib and Vioxx, with a stark warning about the 5-fold MI risk and Vioxx's withdrawal.

  • Page 31: A comparative risk chart places drugs on a spectrum:

    • Very High CV Risk: Diclofenac, Rofecoxib.

    • High CV Risk: Ibuprofen, Celecoxib.

    • Safer (?): Naproxen.

    • CV Protective: Aspirin (at low dose).

• Specific Drug Interactions: Ibuprofen can competitively inhibit the active site of COX-1, counteracting the cardiovascular protective effect of low-dose aspirin.

7.4 COX-2's Putative Role and Other Coxibs

• Hypothesis: COX-2 was thought to have a protective role in the cardiovascular system by producing vasodilatory prostaglandins. Inhibiting it may tip the balance towards vasoconstriction and thrombosis.

• Etoricoxib (Arcoxia, Merck, 2002): Another COX-2 inhibitor. Approved in the UK but not in the USA. It is noted to significantly raise systolic blood pressure and can impair kidney function.

  • Visual (Page 29): Shows the Etoricoxib structure/logo and notes its approval status and blood pressure effect.

SECTION 8: Paracetamol (Acetaminophen)

• Classification: Not an NSAID. Its primary site of action is in the central nervous system (CNS).

• Mechanism: It is a prodrug. Its active metabolite is thought to involve NAPQI, which may desensitize neurons and act as an agonist at certain receptors, although its exact mechanism is not fully elucidated.

• Safety Concerns: Emerging concern over risks of renal, gastrointestinal, and cardiovascular adverse events with chronic/high-dose use.

• Visual (Pages 34-35):

  • Page 34: A simple graphic suggests a brain as the site of action.

  • Page 35: A metabolic pathway shows paracetamol being converted to NAPQI and other metabolites.

SECTION 9: Key Clinical Points & Adverse Effects of NSAIDs

• Deaths: Can occur from anaphylaxis or GI ulcer complications (bleeding, perforation).

• NSAID-Exacerbated Respiratory Disease (NERD): In some asthmatics (especially with nasal polyps), NSAID-induced COX-1 inhibition can trigger a severe asthma attack. This is due to a "shunt" where blocked prostaglandin synthesis leads to increased production of pro-inflammatory leukotrienes.

• Gastroprotection: Due to ulcer risk, NSAIDs are often co-prescribed with gastroprotective agents:

  • Misoprostol (a prostaglandin E₂ analogue).

  • Proton Pump Inhibitors (PPIs).

  • Example: Arthrotec is a combination product containing diclofenac + misoprostol.

• Cardiovascular Risk: COX-2 selective NSAIDs avoid GI bleeding but can carry a high CV risk, possibly due to increased oxidative stress and an imbalance between prostacyclin (anti-thrombotic) and thromboxane (pro-thrombotic).

• Gout: Aspirin can stimulate the renal urate transporter (URAT1), promoting uric acid reabsorption and potentially triggering recurrent gout attacks.

QUESTIONS:

Section 1: Single Best Answer Questions

Q1: Which enzyme in the arachidonic acid pathway is indirectly inhibited by glucocorticoids (steroids) via induction of lipocortin I?
A) Cyclooxygenase (COX)
B) Phospholipase A₂ (PLA₂)
C) Thromboxane synthase
D) Prostacyclin synthase

Answer:

B - Phospholipase A₂ (PLA₂)
Rationale: Steroids activate genes that produce lipocortin I, which inhibits PLA₂, preventing arachidonic acid release from membrane phospholipids. This is upstream of COX inhibition.

Q2:

Why does inhibition of COX-1 by traditional NSAIDs increase the risk of gastric ulcers?
A) It increases gastric acid secretion
B) It reduces prostacyclin (PGI₂) production needed for mucosal protection
C) It directly damages gastric epithelial cells
D) It promotes Helicobacter pylori growth

Answer:

B - It reduces prostacyclin (PGI₂) production needed for mucosal protection
Rationale: COX-1 produces PGH₂, which is converted to PGI₂ in the stomach. PGI₂ maintains mucosal blood flow and mucus secretion. NSAID inhibition of COX-1 reduces PGI₂, leaving mucosa vulnerable to acid damage.

Q3:

Which structural feature allows COX-2 selective inhibitors (coxibs) to preferentially bind COX-2 over COX-1?
A) Smaller molecular size
B) Bulky aromatic substituent that fits COX-2's larger side pocket
C) Positive charge that interacts with COX-2's arginine residue
D) Sulfhydryl group that forms disulfide bonds

Answer:

B - Bulky aromatic substituent that fits COX-2's larger side pocket
Rationale: COX-2 has a more spacious hydrophilic side pocket (valine at position 523) versus COX-1's smaller pocket (isoleucine). Coxibs have bulky groups (e.g., sulfonamide in celecoxib) that fit COX-2 but not COX-1.

Q4:

In NSAID-exacerbated respiratory disease (NERD), why do NSAIDs trigger asthma attacks in susceptible individuals?
A) Direct bronchoconstriction via histamine release
B) Shunt from blocked prostaglandin synthesis to increased leukotriene production
C) IgE-mediated anaphylactic reaction to NSAIDs
D) Inhibition of β₂-adrenergic receptors in bronchial smooth muscle

Answer:

B - Shunt from blocked prostaglandin synthesis to increased leukotriene production
Rationale: In NERD, COX-1 inhibition reduces protective PGE₂, shifting arachidonic acid metabolism to the lipoxygenase pathway → increased cysteinyl leukotrienes (LTC₄, LTD₄) → bronchoconstriction and inflammation.

Section 2: Extended Matching Questions

Theme: Drug Mechanisms in Arachidonic Acid Pathway

Options:
A) Inhibits PLA₂ indirectly via lipocortin induction
B) Irreversibly acetylates COX-1 active site
C) Reversibly inhibits COX-1 and COX-2
D) Selectively inhibits COX-2 via bulky group binding
E) Prodrug metabolized to NAPQI with central action

Q1:

Prednisolone (glucocorticoid)

Answer:

A - Steroids induce lipocortin → inhibits PLA₂.

Q2:

Aspirin

Answer:

B - Irreversibly acetylates serine 530 in COX active site.

Q3)

Ibuprofen

Answer:

C - Reversible competitive inhibitor of both COX isoforms.

Q4)

Celecoxib (Celebrex)

Answer:

D - COX-2 selective via sulfonamide group in side pocket.

Theme: Clinical Consequences of COX Inhibition

Options:
A) Gastric ulceration/bleeding
B) Impaired platelet aggregation
C) Myocardial infarction/stroke
D) Asthma exacerbation (NERD)
E) Gout flare

Q1:

Due to reduced gastric PGI₂ from COX-1 inhibition

Answer:

A - Loss of mucosal protection.

Q2)

From irreversible COX-1 inhibition in platelets (7-10 day effect)

Answer:

B - Aspirin's antiplatelet effect lasts platelet lifespan.

Q3)

Associated with COX-2 inhibition altering prostacyclin/thromboxane balance

Answer:

C - CV risk from coxibs and some traditional NSAIDs.

Q4)

Leukotriene shunt from COX inhibition in susceptible asthmatics

Answer:

D - NSAID-exacerbated respiratory disease.

Section 3: Clinical Scenario - NSAID Selection

Scenario: Mr. Evans, 68, with osteoarthritis of knees, hypertension (controlled), history of peptic ulcer 5 years ago (H. pylori treated). Needs regular analgesia. BP 135/85, eGFR 65 mL/min.

Q: Compare and contrast NSAID options including traditional NSAIDs, COX-2 inhibitors, and paracetamol, considering efficacy, safety, and patient-specific factors.

In-depth Answer:

RISK ASSESSMENT:

• GI risk: High (age >65, previous ulcer)

• CV risk: Moderate (age, hypertension)

• Renal risk: Moderate (age, eGFR 65)

OPTION 1: TRADITIONAL NSAID (e.g., Naproxen 500mg BD)

• Efficacy: Good for OA pain/inflammation

• GI risk: High - requires PPI co-prescription (omeprazole 20mg OD)

• CV risk: Lower than other NSAIDs (neutral in studies)

• Renal: May reduce GFR, cause fluid retention → worsen HTN

• Practical: Low cost, OTC availability

• For Mr. Evans: Not ideal due to ulcer history despite PPI

OPTION 2: COX-2 SELECTIVE INHIBITOR (Celecoxib 200mg OD)

• Efficacy: Similar to traditional NSAIDs

• GI risk: Lower than non-selective (but still some risk - needs PPI with ulcer history)

• CV risk: Higher than naproxen (relative risk ~1.5)

• Renal: Similar fluid retention risk

• Cost: Higher (£10-£20/month)

• For Mr. Evans: Better GI profile but concerning CV risk with hypertension

OPTION 3: PARACETAMOL (1g QDS regular)

• Efficacy: Moderate for OA pain (less anti-inflammatory)

• GI risk: Minimal at therapeutic doses

• CV/renal risk: Minimal

• Hepatic risk: Dose-dependent (max 4g/day)

• Recent concerns: Emerging data on CV/GI risks with chronic high-dose

• For Mr. Evans: Safest first-line, but may be insufficient for moderate-severe OA

OPTION 4: TOPICAL NSAID (Diclofenac gel 1% TDS)

• Efficacy: Good for localized knee OA

• Systemic exposure: ~6% of oral → much lower GI/CV/renal risk

• Practical: Requires application 3x daily

• For Mr. Evans: Excellent option for knee-specific pain

RECOMMENDED HIERARCHICAL APPROACH:

Step 1: Non-pharmacological

• Weight loss (if overweight), exercise, knee braces, physiotherapy

Step 2: Regular paracetamol

• 1g QDS scheduled (not PRN) for 2-week trial

• Monitor pain diary, liver function if long-term

Step 3: Add topical NSAID

• Diclofenac gel to knees TDS

• Continue paracetamol

Step 4: If inadequate → Oral NSAID with maximal protection

• Choice: Naproxen 500mg BD + omeprazole 20mg OD

• Rationale: Better CV profile than celecoxib for hypertensive patient

• Monitoring: BP weekly (NSAIDs raise BP), renal function at 1 month

• Duration: Shortest possible, intermittent rather than continuous

AVOID:

• Ibuprofen: Higher CV risk than naproxen

• Diclofenac oral: High CV risk

• Aspirin: Not for analgesia in this case (gastric risk)

SPECIAL CONSIDERATIONS:

• H. pylori status: Confirm eradication (breath test)

• PPI timing: Omeprazole before breakfast, separate from other medications

• BP control: May need antihypertensive adjustment if NSAID started

EDUCATION:

• "Take with food" (traditional NSAIDs)

• "Report black stools, abdominal pain" (GI bleeding)

• "Watch for ankle swelling" (fluid retention)

• "Don't take OTC NSAIDs in addition"

ALTERNATIVE ANALGESIA:

• Consider: Capsaicin cream, duloxetine (central pain modulation)

• If severe: Refer orthopedics for injection/surgery

DOCUMENTED PLAN:

1. Trial paracetamol 1g QDS + topical diclofenac gel

2. If inadequate after 4 weeks, consider naproxen 500mg BD + omeprazole 20mg OD

3. Regular BP, renal monitoring

4. Annual GI risk reassessment

Section 4: COX-2 Inhibitor Controversy & Mechanisms

Scenario: A patient asks why Vioxx (rofecoxib) was withdrawn but Celebrex (celecoxib) remains available, given both are COX-2 inhibitors.

Q: Explain the scientific and clinical differences between these coxibs, including structural selectivity, cardiovascular mechanisms, and current risk understanding.

In-depth Answer:

STRUCTURAL & SELECTIVITY DIFFERENCES:

Rofecoxib (Vioxx):

• Structure: Methylsulfone group as bulky substituent

• COX-2 selectivity: ~300-fold over COX-1 (highly selective)

• Half-life: ~17 hours (long)

• Dosing: Once daily

Celecoxib (Celebrex):

• Structure: Sulfonamide group

• COX-2 selectivity: ~30-fold over COX-1 (moderately selective)

• Half-life: ~11 hours

• Dosing: Once or twice daily

Key difference: Rofecoxib's higher selectivity and longer half-life may have contributed to more profound and sustained COX-2 inhibition.

CARDIOVASCULAR MECHANISM OF HARM:

Proposed pathway:

1. COX-2 inhibition reduces vascular PGI₂ (prostacyclin) production

2. PGI₂ is vasodilatory and inhibits platelet aggregation

3. With COX-2 inhibited, thromboxane A₂ (TXA₂) from platelet COX-1 dominates

4. TXA₂ is vasoconstrictive and pro-thrombotic

5. Result: Pro-thrombotic state → increased MI/stroke risk

Additional factors:

• Blood pressure: COX-2 inhibitors increase systolic BP by ~3-5 mmHg (more than some traditional NSAIDs)

• Oxidative stress: May promote atherosclerosis progression

• Renal effects: Fluid retention exacerbates hypertension

THE VIOXX SCANDAL SPECIFICS:

APPROVe trial findings (2004):

• 5-fold increased MI risk vs. placebo after 18 months

• Absolute risk: 1.5% vs. 0.25%

• Risk emerged after 12-18 months of continuous use

• Merck accused of withholding early data

Why celecoxib survived:

1. Lower selectivity: Some COX-1 inhibition may provide partial platelet effect

2. Shorter half-life: Less sustained inhibition

3. Different chemical class: Sulfonamide vs. methylsulfone

4. Subsequent trials: Showed lower CV risk than rofecoxib (but still elevated vs. naproxen)

CURRENT UNDERSTANDING OF NSAID CV RISK:

Risk hierarchy (high to low):

1. Highest: Rofecoxib (withdrawn), diclofenac

2. High: Celecoxib, ibuprofen (high dose)

3. Moderate: Naproxen (lowest CV risk among NSAIDs)

4. Protective: Low-dose aspirin (antiplatelet)

Factors modifying risk:

• Dose/duration: Higher doses and longer use increase risk

• Patient factors: Existing CVD, hypertension, diabetes multiply risk

• Concomitant aspirin: May mitigate but not eliminate risk

CLINICAL GUIDANCE TODAY:

Celecoxib use is appropriate when:

• High GI risk (e.g., previous ulcer, elderly)

• Low CV risk profile

• Used at lowest effective dose, shortest duration

• With PPI if GI risk factors present

• Avoided in established CVD

Monitoring on COX-2 inhibitors:

• BP monitoring (weekly initially)

• CV symptom awareness (chest pain, SOB)

• Regular benefit-risk reassessment

PATIENT COUNSELING POINTS:

• "COX-2 drugs are easier on the stomach but harder on the heart"

• "Celecoxib is safer than Vioxx was, but still carries some heart risk"

• "We use them when stomach protection is more important than heart risk"

• "Never use them longer than needed"

BOTTOM LINE: Rofecoxib's high selectivity + long half-life + delayed risk detection led to withdrawal. Celecoxib has lower selectivity and is used with caution in selected patients. All NSAIDs have CV risks—the key is matching drug to individual patient risk profile.

Section 5: Special Populations & Contraindications

Scenario: Compare NSAID use considerations in:

• Patient A: 28-year-old with NSAID-exacerbated respiratory disease (NERD), nasal polyps, and asthma

• Patient B: 72-year-old with heart failure (EF 40%), CKD stage 3 (eGFR 45), needing OA pain relief

Q: Analyze the specific risks, alternative options, and management strategies for each high-risk patient.

In-depth Answer:

PATIENT A: NERD + ASTHMA + NASAL POLYPS (SAMTER'S TRIAD)

Pathophysiology:

• COX-1 inhibition → reduced PGE₂ (bronchodilatory/anti-inflammatory)

• Shunt to lipoxygenase pathway → increased cysteinyl leukotrienes (LTC₄, LTD₄)

• Results: Bronchospasm, nasal congestion, potentially life-threatening

Absolute contraindications:

• All traditional NSAIDs (non-selective COX inhibitors)

• Possibly COX-2 inhibitors (cross-reactivity in ~10% of NERD patients)

Alternative analgesia:

1. Paracetamol: Usually safe (but test with small dose initially - rare cross-reactivity)

2. Opioids: Weak opioids (codeine, tramadol) if needed

3. Other: Gabapentin/pregabalin for neuropathic pain components

ASA desensitization protocol:

• Indication: For patients needing NSAIDs/aspirin (e.g., cardiac indications)

• Process: Gradual dose escalation under medical supervision

• Maintenance: Daily aspirin/NSAID to maintain tolerance

• Not for: Simple analgesia needs

Management of acute reaction:

• Stop NSAID immediately

• Bronchodilators (salbutamol nebulizer)

• Systemic steroids (prednisolone 40mg OD)

• Monitor in hospital if severe

Education:

• "Avoid all NSAIDs including OTC products"

• "Check ingredients in combination products"

• "Wear medical alert bracelet"

• "Carry emergency asthma action plan"

PATIENT B: HEART FAILURE + CKD + ELDERLY

Risks of NSAIDs:

1. Fluid retention: Worsens heart failure, may precipitate pulmonary edema

2. Renal: Reduces GFR further via prostaglandin inhibition (afferent arteriole vasoconstriction)

3. Hypertension: Antagonizes antihypertensives

4. Hyperkalaemia: Especially with ACEi/ARB

5. GI bleeding: Age + possible anticoagulant use

Safer alternatives:

1. Topical NSAIDs: First-line (diclofenac gel)

2. Paracetamol: Regular dosing (monitor liver function)

3. Low-dose opioids: With laxative prophylaxis (avoid in severe CKD)

4. Non-drug: Physiotherapy, TENS, weight loss

If NSAID absolutely necessary:

• Choice: Naproxen (lowest CV risk) at lowest dose

• PPI: Mandatory (omeprazole)

• Monitoring:

  • Daily weights (fluid status)

  • Weekly renal function, potassium

  • Regular symptom review

• Duration: Shortest possible (e.g., 5-7 days)

Heart failure-specific concerns:

• NSAIDs reduce diuretic efficacy

• May increase mortality in CHF

• Consider specialty pain management referral

Renal dosing adjustments:

• eGFR 30-60: Reduce NSAID dose by 25-50%

• eGFR <30: Avoid NSAIDs if possible

• Hydration: Ensure adequate but not excessive fluid intake

COMPARATIVE TABLE:

SPECIALIST INVOLVEMENT:

• Patient A: Allergist/immunologist for desensitization if needed

• Patient B: Cardiorenal clinic for complex management

DOCUMENTATION:

• Clear contraindications listed in records

• Patient education provided

• Alternative plan documented

• Safety-netting instructions given

PREVENTIVE APPROACH:

• Both patients: Regular review of analgesia needs

• Consider: Disease-modifying agents for underlying conditions (e.g., biologics for severe asthma, SGLT2 inhibitors for HF/CKD)

• Multidisciplinary: Pain team, pharmacist, specialist physician collaboration

KEY MESSAGE: In high-risk patients, avoid NSAIDs when possible. Use alternative strategies and if NSAIDs are essential, choose the least harmful option with aggressive monitoring and protection.